GSK Jan 2025 32.000 call
| Previous close | 8.39 |
| Open | 8.39 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 32.00 |
| Expiry date | 2025-01-17 |
| Day's range | 8.39 - 8.39 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Evening StandardFTSE 100 Live 1 May: GSK, Next and Smith & Nephew in focus, shares edge up before Fed call
Upgraded profit guidance by GSK stood out today in a session featuring updates by Next, Smith & Nephew and Sensodyne business Haleon. The quartet all signalled robust trading at the start of 2024, helping the FTSE 100 index to begin May in resilient fashion. Traders are also looking ahead to tonight’s US Federal Reserve decision and whether September is still the most likely month for the first cut.
ReutersGSK raises 2024 profit forecast but says sales growth to slow in 2nd half
(Reuters) -GSK raised its full-year profit forecast on Wednesday on strong demand for vaccines and specialty medicines though it noted sales growth would slow in the second half. CEO Emma Walmsley's strategy has focussed on vaccines and infectious diseases and a shift in its HIV focus to long-acting treatment and prevention therapies. It expects 2024 sales to grow in the upper end of its 5% to 7% forecast range.
Fool.co.ukI’ve just met Warren Buffett’s first rule of investing. Here are 3 ways I did it
Harvey Jones has surprised himself by living up to Warren Buffett's most important investment rule. But is his success down to luck or judgement? The post I’ve just met Warren Buffett’s first rule of investing. Here are 3 ways I did it appeared first on The Motley Fool UK.
